Onconova Therapeutics Inc.

229 articles about Onconova Therapeutics Inc.

• Onconova Therapeutics Announces Participation in the Channelchek Takeaway Series

  1/26/2023

  Onconova Therapeutics, Inc. today announced their participation in the Channelchek Takeaway Series from the J.P.Morgan Healthcare Conference, to be broadcast Thursday, January 26, starting at 10:00 EST.

• Onconova Therapeutics Appoints Drs. Peter Atadja and Trafford Clarke to its Board of Directors

  12/19/2022

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the appointments of Peter Atadja, Ph.D., and Trafford Clarke, Ph.D., as independent members of the Company’s Board of Directors.

• Onconova Therapeutics to Present at the Upcoming MedInvest Oncology Investor Conference

  12/7/2022

  Onconova Therapeutics, Inc. today announced that it will participate in the MedInvest Oncology Investor Conference being held in New York, NY on December 14-15, 2022.

• Onconova Therapeutics to Present at the Upcoming RHK Capital Disruptive Growth Conference

  11/28/2022

  Onconova Therapeutics, Inc. today announced that it will participate in the RHK Capital Disruptive Growth Conference being held in the offices of Reed Smith in New York, NY on December 5-6, 2022.

• Onconova Therapeutics Announces Plans for a Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer, Reports Third Quarter 2022 Financial Results, and Provides a Business Update

  11/14/2022

  Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced plans for a Phase 1/2a trial of narazaciclib combined with letrozole in recurrent metastatic low-grade endometrioid endometrial cancer.

• Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter Financial Results on November 14, 2022

  11/7/2022

  Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced that the Company intends to release its third quarter 2022 financial results on Monday, November 14, 2022.

• Onconova Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare Conference

  9/22/2022

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating in-person in the Ladenburg Thalmann 2022 Healthcare Conference, which is taking place at the Sofitel Hotel in New York, NY.

• Onconova Therapeutics Announces Updated Data from Investigator-sponsored Phase 1/2a Trial Evaluating Rigosertib in Combination with Nivolumab in Advanced KRAS-mutated Non-Small Cell Lung Cancer at the ESMO Congress 2022

  9/12/2022

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”) today announced updated data from an investigator-sponsored Phase 1/2a trial of oral rigosertib plus the anti-PD-1 immune checkpoint inhibitor (ICI) nivolumab in advanced KRAS-mutated (KRAS+) non-small cell lung cancer (NSCLC).

• Onconova Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

  9/1/2022

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating virtually in the H.C. Wainwright 24th Annual Global Investment Conference.

• Onconova Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

  8/11/2022

  Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced financial results for the three months ended June 30, 2022, and provided a business update.

• Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter Financial Results on August 11, 2022

  8/4/2022

  Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced that the Company intends to release its second quarter 2022 financial results on Thursday, August 11, 2022.

• 

  BioSpace Movers & Shakers: ADC, Akari, Scorpion & More

  6/17/2022

  This week's Movers & Shakers includes a number of chief business officers and business development leaders alongside those tapped for scientific roles.

• Onconova Therapeutics Announces Key Management Promotions

  6/13/2022

  Onconova Therapeutics, Inc. today announced that Mark Guerin was appointed Chief Operating Officer in addition to his current role as Onconova's Chief Financial Officer (CFO), and that Dr. Adar Makovski Silverstein was appointed Senior Director and Head of Corporate Development.

• Onconova Therapeutics Announces Abstract at the ASCO Annual Meeting Highlighting Narazaciclib’s Differentiated Inhibitory and Improved Safety Profile in Preclinical Models

  5/26/2022

  Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced the publication of an abstract at the American Society of Clinical Oncology Annual Meeting.

• Onconova Therapeutics Reports First Quarter 2022 Financial Results and Provides Business UpdateConference call and live webcast at 4:30 p.m. ET today

  5/11/2022

  Onconova Therapeutics, Inc. announced financial results for the three months ended March 31, 2022, and provided a business update.

• Onconova Therapeutics to Provide Corporate Update and Announce First Quarter Financial Results on May 11, 2022

  5/4/2022

  Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced that the Company intends to release its first quarter 2022 financial results on Wednesday, May 11, 2022.

• Onconova Therapeutics Announces Acceptance of Abstract for Publication at the ASCO Annual Meeting

  4/27/2022

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the acceptance of an abstract for publication at the American Society of Clinical Oncology (ASCO) Annual Meeting.

• Onconova Therapeutics to Present at the Next Generation Kinase Inhibitors Summit

  3/23/2022

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Adar Makovski Silverstein, Ph.D., Director of Corporate Development for Onconova, will present a high-level overview of the Company’s narazaciclib program at the Next Generation Kinase Inhibitors Summit on March 30, 2022, at 2:00 p.m. ET.

• Onconova Therapeutics Reports Full Year 2021 Financial Results and Provides Business Update

  3/17/2022

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced financial results for the twelve months ended December 31, 2021, and provided a business update.

• Onconova Therapeutics to Provide Corporate Update and Announce Fourth Quarter and Full Year 2021 Financial Results on March 17, 2022

  3/10/2022

  Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced that the Company intends to release its fourth quarter and full year 2021 financial results on Thursday, March 17, 2022.